FDA Places REGENXBIO’s RGX-121 on Clinical Hold After Spine MRI Findings

Company: REGENXBIO · Asset: RGX-121 (Clemidsogene Lanparvovec) · Indication: Neuronopathic MPS II · Event Type: FDA Clinical Hold · Date: August 24, 2026 Summary FDA placed the RGX-121 program on clinical hold after asymptomatic spinal MRI findings were identified in five CAMPSIITE participants treated approximately…